Recent research articles.
Loss of lipid carrier ApoE exacerbates brain glial and inflammatory responses after lysosomal GBA1 inhibition
Connolly KJ, Margaria J, Di Biase E, Cooper O, Hallett PJ, Isacson O. Cells (2023) Nov 2.
Viral-like TLR3 induction of cytokine networks and α-synuclein are reduced by complement C3 blockade in mouse brain
Thomas R, Connolly KJ, Brekk OR, Hinrich AJ, Hastings ML, Isacson O, Hallett PJ. Sci Rep (2023) Sep 13.
Upstream lipid and metabolic systems are potential causes of Alzheimer’s disease, Parkinson’s disease and dementias
Cooper O, Hallett PJ and Isacson O. FEBSJ (2022) Sep 27.
Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
Wallom KL, Fernández-Suárez ME, Priestman DA, Te Vruchte D, Huebecker M, Hallett PJ, Isacson O, Platt FM. Glycoconj J. (2021) Nov 10.
Fibroblasts from idiopathic Parkinson’s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2
Thomas R, Moloney EB, Macbain ZK, Hallett PJ, and Isacson O. Mol. Brain (2021) Jan 19.
Cell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance
Brekk OR, Honey JR, Lee S, Hallett PJ, and Isacson O. PNAS (2020) Oct 15.
Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicity
Brekk OR. Korecka JA, Crapart CC, Huebecker M, MacBain ZK, Rosenthal SA, Sena-Esteves M, Priestman DA, Platt FM, Isacson O and Hallett PJ. Acta Neuropathologica Communications (2020) 8:127.
Splice-switching antisense oligonucleotides reduce LRRK2 kinase activity in human LRRK2 transgenic mice
Korecka JA, Thomas R, Hinrich AJ, Moskites AM, Macbain ZK, Hallett PJ, Isacson O, Hastings ML. Mol. Ther. Nuc. Acids. 2020, 21:623.
The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable
Isacson O. Front. Neurol., 24 July 2020
Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients.
Osborn TM, Hallett PJ, Schumacher JM, Isacson O.Front Cell Neurosci. 2020 Apr 3;14:58. doi: 10.3389/fncel.2020.00058. eCollection 2020.
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.
Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Mol Neurodegener. 2019 Nov 8;14(1):40.
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease.
Hallett PJ, Engelender S, Isacson O. J Neuroinflammation. 2019 Jul 22;16(1):153. doi: 10.1186/s12974-019-1532-2.
Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease
Isacson O, Brekk O, Hallett PJ Front. Neurol., 2019; 10, Article 1053.
Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.
Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, Hastings ML, Hallett PJ, Isacson O Hum Mol Genet., 2019
Neurite Collapse and altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation.
Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, Moskites A, Atkinson E, Jodelka FM, Hinrich AJ, Hastings ML, Woolf CJ, Hallett PJ, Isacson O. Stem Cell Reports., 2019 Jan;12:29-41.
Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age.
Brekk OR, Moskites A, Isacson O, Hallett PJ. Scientific Reports., 2018 Oct;8:15207.
The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress.
Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ.Neurobiol Dis., 2018 Aug;120:1-11.
Previous research articles.
Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain.
Hallett et al. Neurobiol Aging, 2018. Mar;67:189-200.
PDF
Increased motor neuron resilience by small molecule compounds that regulate IGF-II expression.
Osborn TM, Beagan J, Isacson O. Neurobiol Dis., 2018 Feb;110:218-230.
PDF
Integrated Molecular Landscape of Parkinson's Disease
Kiemann et al. npj Parkinson's Disease, 2017. Apr;3(14).
The Threshold Theory for Parkinson's Disease.
Engelender S. Isacson O. Trends Neurosci., 2017. Jan;40(1): 4-14.
PDF
Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
Smith et al. Mol Neurobiol, 2016. Oct;53(8):5161-77.
PDF
In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells.
Korecka et al. Mol Cell Neurosci, 2016. June;73:3-12.
PDF
Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons.
Rocha et al. Neurobiol Dis, 2015. Sept. 25, 2015.
PDF
Progressive decline of glucocerebrosidase in aging and Parkinson's disease.
Rocha et al. Ann Clin Transl Neurol, 2015 • 23(6), Apr. 2, 2015.
PDF
Sustained Systemic Glucocerebrosidase Inhibition Induces Brain a-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha et al. Antioxidants & Redox Signaling, 2015. 23(6).
PDF
A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).
Smith et al. PLoS One, 2015 • 10(3), Mar. 27, 2015.
PDF
Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease
Cell Stem Cell, 2015. 16, 269-274.
PDF
Long-term health of dopaminergic neuron transplants in Parkinson's disease patients
Cell Reports, 2014, 7:1755-61.
PDF
Progressive axonal transport and synaptic protein changes correlate with behavioral and neurpathological abnormalities in the heterozygous Q175KI mouse model of Huntington's disease
Human Molecular Genetics, April 30, 2014.
PDF
LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction
Neurobiology of Disease, 2014. 62:381-386.
PDF
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson's Disease
Science Transl Med, July 4, 2012 • 4:52-64
PDF
Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.
Neurobiol Dis,Apr. 19, 2012 •47:258-67.
PDF
Viral and Inflammatory Triggers of Neurodegenerative Diseases.
Science Transl Med, Feb 15, 2012 . 4:121-3.
PDF